Parisa Shamsesfandabadi | Radiation oncology | Best Researcher Award

Dr. Parisa Shamsesfandabadi | Radiation oncology | Best Researcher Award

Dr. Parisa Shamsesfandabadi ๐Ÿ‡บ๐Ÿ‡ธ is a passionate radiation oncologist with a dynamic academic and clinical background, currently serving as Chief Resident at Allegheny Health Network in Pittsburgh, PA ๐Ÿ’ผ. She combines a global medical foundation from Iran with extensive U.S. clinical training ๐Ÿ‡ฎ๐Ÿ‡ทโžก๏ธ๐Ÿ‡บ๐Ÿ‡ธ. Driven by innovation and compassion, Parisa has earned national recognition with multiple prestigious awards ๐Ÿ…. Her dedication extends beyond clinical excellence to impactful research, global health, and mentorship ๐ŸŒ๐Ÿ“š. With hands-on experiences at leading institutions like Duke, UNC, and VA Medical Center, her expertise spans brain, breast, liver, and prostate cancer research ๐Ÿง ๐Ÿ’ช. Parisaโ€™s unique blend of research, service, and leadership reflects her lifelong commitment to patient care, academic excellence, and transformative cancer therapy ๐ŸŒŸ. In addition to her clinical role, she actively contributes as an editorial assistant, social ambassador, and peer-reviewer to renowned medical journals and organizations ๐Ÿ“–๐Ÿค. She’s a true rising star in oncology ๐Ÿš€.

Profile

Education ๐ŸŽ“

๐Ÿ“ Chief Resident, Radiation Oncology โ€“ Allegheny Health Network, PA (2024โ€“Present) ๐Ÿ‘ฉโ€โš•๏ธ
๐Ÿ“ Residency, Radiation Oncology โ€“ Allegheny Health Network, PA (2019โ€“2024) ๐Ÿ’‰
๐Ÿ“ Internship (PGY-1), Transitional Year โ€“ Southern Hills Hospital, Las Vegas, NV (2019โ€“2020) ๐Ÿฅ
๐Ÿ“ M.D. โ€“ Kashan University of Medical Sciences, Iran (2007โ€“2014) ๐ŸŽ“๐Ÿ‡ฎ๐Ÿ‡ท
๐Ÿ“ High School โ€“ Tehran Farzanegan School, NODET (2000โ€“2007) ๐Ÿง ๐Ÿซ
Parisa’s academic journey reflects brilliance from the start, attending Iranโ€™s elite NODET school ๐ŸŒŸ. She pursued medicine at KaUMS, consistently ranking top in medical Olympiads ๐Ÿฅ‡. Her U.S. medical training includes internship and residency in highly reputed institutions, leading to her current leadership as Chief Resident ๐Ÿง‘โ€โš•๏ธ. Her academic record is peppered with awards, research, and international training, preparing her for a successful future as a physician-scientist and leader in cancer care ๐Ÿงฌ๐Ÿฉบ.

Experience ๐Ÿ‘จโ€๐Ÿซ

๐Ÿ“ Chief Resident, Radiation Oncology โ€“ AHN (2024โ€“Present)
๐Ÿ“ Research Associate โ€“ VA Medical Center, Durham, NC ๐Ÿงช
๐Ÿ“ Visiting Scholar โ€“ Duke, UNC, CCC Las Vegas ๐Ÿซ
๐Ÿ“ Research Visitor โ€“ RAI Lab, Duke University (Glioma Imaging) ๐Ÿง 
๐Ÿ“ Research Associate โ€“ KaUMS, Iran (Probiotics Study) ๐Ÿงƒ
๐Ÿ“ Medical Assistant โ€“ Advanced Pain Management, NV ๐Ÿ’Š
๐Ÿ“ Volunteer โ€“ Rural Clinics, Pediatrics & Geriatrics Programs ๐Ÿง’๐Ÿ‘ต
๐Ÿ“ Editorial Assistant โ€“ eContour ๐Ÿ“˜
๐Ÿ“ Communications Intern โ€“ RTOG Foundation ๐Ÿ’ฌ
Dr. Parisa brings a rich portfolio of clinical and research experience across top U.S. and international institutions ๐ŸŒ. From clinical research on prostate and brain cancers to hands-on patient care and administrative duties, she is known for her leadership, empathy, and academic dedication ๐Ÿฅ๐Ÿง ๐Ÿ“Š.

Awards & Recognitions ๐Ÿ…

๐ŸŽ– 2024 RTOG Communications Intern
๐Ÿ’ฐ 2023 $25K Grant โ€“ MRLinac Sarcoma (Benedum Foundation)
๐Ÿงณ 2023 Travel Grants โ€“ ARS, ACRO, ACR
๐Ÿฅ‡ 2022 Resident Best Abstract โ€“ ABS
๐ŸŽ– 2022 Editorial/Fellow Roles โ€“ eContour, The Mednet, NRG
๐ŸŒŸ 2022 RePRT Peer Reviewer โ€“ Red Journal
๐Ÿ† 2022 Travel Award โ€“ eContour Vulvar Cancer Guidelines
๐Ÿ‘ฉโ€๐ŸŽ“ Olympiad Champion โ€“ 4x Gold in Iran Medical Olympiads
๐Ÿง  UNESCO Youth Award โ€“ Earthquake Awareness Project
๐Ÿ… Sharif University Medal โ€“ Math & Graphs Competition
๐Ÿงช Ranked 1st in Nationwide Chemistry Lab Exam
๐Ÿ“• Published Short Book โ€“ โ€œWorld of Animalsโ€
๐Ÿ“š Parisaโ€™s excellence is recognized through national and international grants, editorial roles, peer-review selections, and top medical student honors ๐Ÿ…. From early academic brilliance to clinical and research impact, her accolades reflect a rare blend of intellect, service, and innovation ๐ŸŒโœจ.

Research Interests ๐Ÿ”ฌ

๐Ÿง  Radiogenomics โ€“ Brain Cancer Imaging (Duke, UNC)
๐Ÿงฌ MR-Linac SBRT โ€“ Liver, Pancreatic, Prostate, and Breast Cancers
๐Ÿ’ช Strength Training Impact โ€“ Radiotherapy in Breast Cancer
๐Ÿงฒ Adaptive Radiation Therapy โ€“ CBCT, MRI-based Comparisons
๐Ÿ” Treatment Planning โ€“ Monte Carlo vs Cone Algorithm
๐Ÿงซ Biomarker Evaluation โ€“ Breast Cancer (KaUMS & Leiden University)
๐Ÿงƒ Probiotics vs Regular Yogurt in Pediatric Diarrhea
๐Ÿ–ฅ Editorial & Peer Review Roles โ€“ Red Journal, The Mednet, eContour
Dr. Shamsesfandabadiโ€™s research bridges advanced imaging, functional planning, and personalized therapy in oncology ๐Ÿง . Her projects focus on enhancing precision radiation therapy using radiogenomics, AI-driven adaptive planning, and improving survivorship through integrative approaches ๐Ÿ’ป๐Ÿ’ก. Sheโ€™s driven to optimize outcomes in patients with complex cancers like gliomas, HCC, and pancreatic malignancies, while actively contributing to guidelines and clinical trials ๐Ÿงช๐Ÿ’ฅ. A rising voice in the next-gen of physician-scientists ๐ŸŒŸ.

Publicationsย 
  • -Kirichenko, A., Uemura, T., Hasan, S., Lian, Y., Abel, S., Renz, P.,
    Shamsesfandabadi, P., Carpenter, J., Thai, N., โ€œStereotactic Body Radiotherapy
    (SBRT) for Hepatocellular Carcinoma (HCC) with Single Photon Emission
    Computed Tomography (SPECT) Functional Treatment Planning in Patients with
    Advanced Hepatic Cirrhosis.โ€ Advances in Radiation Oncology (Accepted,
    July 2023).
  • Goss, M., Champ, C., Trombetta, M, Shamsesfandabadi, P., DeMartino, V.,
    Wegner, R., Beriwal, S., Eisen, V. โ€œThe Comparison of Collapsed Cone and
    Monte Carlo Algorithms in Tangential Breast Planning.โ€ Journal of Radiotherapy
    in Practice. (April 2023).
  • Mazurowski, M.A., Clark, K., Czarnek, N. M., Shamsesfandabadi, P., et al.
    โ€œRadiogenomics of lower-grade glioma: algorithmically assessed tumor shape
    is associated with tumor genomic subtypes in a multi-institutional study with
    The Cancer Genome Atlas data.โ€ Journal of Neuro-Oncology. 2017, May;
    133(1): 27-35. Cited in PubMed; PMID: 28470431.
  • Mazurowski, M. A., Clark, K., Czarnek, N. M., Shamsesfandabadi, P., et al.
    (2017, March 21). โ€œRadiogenomic analysis of lower grade glioma: a pilot multiinstitutional study shows an association between quantitative image features
    and tumor genomics.โ€ SPIE, The international society for optics and photonics.
  • – Sharif, A., Kheirkhah, D., Shamsesfandabadi, P., et al. โ€œComparison of Regular
    and Probiotic Yogurts in Treatment of Acute Watery Diarrhea in Children.โ€
    Journal of Probiotics and Health. 2016, Feb; 5(1): 164.

Nuo Yu | Radiomics | Best Researcher Award

Ms. Nuo Yu | Radiomics | Best Researcher Award

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College ,China

Nuo Yu is a Ph.D. candidate at the Cancer Institute and Hospital of the Chinese Academy of Medical Sciences, specializing in radiation oncology with a focus on esophageal squamous cell carcinoma (ESCC). His research primarily explores innovative chemoradiotherapy regimens to improve treatment outcomes for patients with locally advanced ESCC.

Yu has contributed to several peer-reviewed publications in SCI-indexed journals. Notably, he co-authored a study titled “Conversion Chemoradiotherapy Combined with Nab-Paclitaxel Plus Cisplatin in Patients with Locally Advanced Borderline-Resectable or Unresectable Esophageal Squamous Cell Carcinoma: A Phase I/II Prospective Cohort Study,” published in Strahlentherapie und Onkologie in August 2024. This research evaluated the efficacy and safety of a novel chemoradiotherapy regimen, demonstrating promising results in locoregional control and overall survival rates.

In March 2023, Yu co-authored another significant study, “Efficacy and Safety of Concurrent Chemoradiotherapy Combined with Nimotuzumab in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Prospective Real-world Pragmatic Study,” published in Current Cancer Drug Targets. This research focused on treatment strategies for elderly patients with ESCC, highlighting the potential benefits of combining chemoradiotherapy with nimotuzumab.

Yu’s work has been recognized at international conferences, including presentations at the American Society for Radiation Oncology (ASTRO), the Federation of Asian Organizations for Radiation Oncology (FARO), and the Korean Society for Radiation Oncology (KOSRO). These engagements underscore his active participation in the global radiation oncology community and his commitment to advancing cancer treatment research.

While still in the early stages of his career, Yu’s focused research on ESCC and his contributions to the field of radiation oncology position him as a promising candidate for the Best Researcher Award. Continued efforts to expand his research scope, increase publication impact, and assume leadership roles in larger-scale studies will further strengthen his candidacy.

Profile

Scientific Publications